Recarbrio 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0021 
Minor change in labelling or package leaflet not 
28/11/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0020 
B.I.a.1.z - Change in the manufacturer of AS or of a 
10/11/2022 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IA/0019 
A.5.b - Administrative change - Change in the name 
27/09/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0017 
B.I.a.2.a - Changes in the manufacturing process of 
26/09/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10830
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202201 
imipenem / cilastatin / relebactam 
IA/0016/G 
This was an application for a group of variations. 
20/07/2022 
n/a 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IA/0015/G 
This was an application for a group of variations. 
10/06/2022 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
WS/2193 
This was an application for a variation following a 
02/06/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
PSUSA/10830
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC Recommendation - maintenance 
/202107 
imipenem / cilastatin / relebactam 
IB/0012/G 
This was an application for a group of variations. 
02/12/2021 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
N/0010 
Minor change in labelling or package leaflet not 
11/10/2021 
24/03/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0009/G 
This was an application for a group of variations. 
16/09/2021 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IB/0008/G 
This was an application for a group of variations. 
02/09/2021 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
PSUSA/10830
Periodic Safety Update EU Single assessment - 
02/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202101 
imipenem / cilastatin / relebactam 
IAIN/0006 
A.5.a - Administrative change - Change in the name 
15/02/2021 
24/03/2022 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10830
Periodic Safety Update EU Single assessment - 
11/02/2021 
n/a 
PRAC Recommendation - maintenance 
/202007 
imipenem / cilastatin / relebactam 
IB/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
29/01/2021 
n/a 
Veterinary Medicinal Products - Other variation 
II/0001 
C.I.6.a - Change(s) to therapeutic indication(s) - 
15/10/2020 
16/11/2020 
SmPC, Annex 
Addition of a new therapeutic indication or 
modification of an approved one 
II and PL 
IAIN/0002 
B.I.e.5.a - Implementation of changes foreseen in an 
12/06/2020 
n/a 
approved change management protocol - Requires 
no further supportive data 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
